Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans
Open Access
- 15 March 2009
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 199 (6), 872-880
- https://doi.org/10.1086/597125
Abstract
BackgroundPolymorphisms in CYP2B6 affect the steady-state plasma concentrations of nevirapine and efavirenz. In many resource-limited countries, a siKeywords
This publication has 29 references indexed in Scilit:
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2008
- Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected IndividualsClinical Pharmacology & Therapeutics, 2007
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6???8 Weeks After Single-Dose Nevirapine (HIVNET 012)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship toCYP2B6Genotype and CAR (Constitutive Androstane Receptor) ExpressionPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2003
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialThe Lancet, 2003
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2003
- Replication validity of genetic association studiesNature Genetics, 2001
- NEVIRAPINE PHARMACOKINETICS IN PREGNANT WOMEN AND IN THEIR INFANTS AFTER IN UTERO EXPOSUREThe Pediatric Infectious Disease Journal, 2001
- Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination TherapyAntimicrobial Agents and Chemotherapy, 2000